AU2003222606A1 - Diagnosis of carcinoma using raigi polypeptides - Google Patents

Diagnosis of carcinoma using raigi polypeptides

Info

Publication number
AU2003222606A1
AU2003222606A1 AU2003222606A AU2003222606A AU2003222606A1 AU 2003222606 A1 AU2003222606 A1 AU 2003222606A1 AU 2003222606 A AU2003222606 A AU 2003222606A AU 2003222606 A AU2003222606 A AU 2003222606A AU 2003222606 A1 AU2003222606 A1 AU 2003222606A1
Authority
AU
Australia
Prior art keywords
polypeptide
cancer
carcinoma
diagnosis
raigi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222606A
Other languages
English (en)
Other versions
AU2003222606A8 (en
Inventor
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208331A external-priority patent/GB0208331D0/en
Priority claimed from GB0221538A external-priority patent/GB0221538D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2003222606A8 publication Critical patent/AU2003222606A8/xx
Publication of AU2003222606A1 publication Critical patent/AU2003222606A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003222606A 2002-04-11 2003-04-10 Diagnosis of carcinoma using raigi polypeptides Abandoned AU2003222606A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0208331.9 2002-04-11
GB0208331A GB0208331D0 (en) 2002-04-11 2002-04-11 Proteins
GB0221538A GB0221538D0 (en) 2002-09-17 2002-09-17 A protein involved in carcinoma
GB0221538.2 2002-09-17
PCT/GB2003/001587 WO2003087832A2 (en) 2002-04-11 2003-04-10 Diagnosis of carcinoma using raigi polypeptides

Publications (2)

Publication Number Publication Date
AU2003222606A8 AU2003222606A8 (en) 2003-10-27
AU2003222606A1 true AU2003222606A1 (en) 2003-10-27

Family

ID=29252443

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222606A Abandoned AU2003222606A1 (en) 2002-04-11 2003-04-10 Diagnosis of carcinoma using raigi polypeptides

Country Status (8)

Country Link
US (2) US20050282165A1 (enExample)
EP (1) EP1497656B1 (enExample)
JP (2) JP2005522226A (enExample)
AT (1) ATE347106T1 (enExample)
AU (1) AU2003222606A1 (enExample)
DE (1) DE60310059T2 (enExample)
ES (1) ES2274220T3 (enExample)
WO (1) WO2003087832A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121362A1 (en) * 2002-06-20 2004-06-24 Whitney Gena S. Identification and modulation of a G-protein coupled receptor (GPCR), RAI-3, associated with chronic obstructive pulmonary disease (COPD) and NF-kappaB and E-selectin regulation
WO2021045224A1 (ja) * 2019-09-04 2021-03-11 国立大学法人東海国立大学機構 がん免疫療法等における免疫関連有害事象の予測

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068618A1 (en) * 2000-07-26 2003-04-10 Muralidharu Padigaru Novel proteins and nucleic acids encoding same
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
AU2002324451A1 (en) * 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer

Also Published As

Publication number Publication date
US20090258019A1 (en) 2009-10-15
ATE347106T1 (de) 2006-12-15
DE60310059T2 (de) 2007-05-10
ES2274220T3 (es) 2007-05-16
JP2005522226A (ja) 2005-07-28
EP1497656B1 (en) 2006-11-29
WO2003087832A2 (en) 2003-10-23
AU2003222606A8 (en) 2003-10-27
WO2003087832A3 (en) 2004-02-12
JP2010117358A (ja) 2010-05-27
EP1497656A2 (en) 2005-01-19
DE60310059D1 (de) 2007-01-11
US20050282165A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
ATE519847T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
WO2002078598A3 (en) Peptides and antibodies to muc 1 proteins
DK0981618T4 (da) Anti-Apo-2-antistof
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE60121346D1 (en) Suppressor-gen
AU2002323120A1 (en) Periostin-based diagnostic assays
WO2001064877A3 (en) Human schizophrenia gene
WO1996031603A3 (en) Methods and compositions for regulating fadd
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DE60031418D1 (de) 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
AU2003222606A1 (en) Diagnosis of carcinoma using raigi polypeptides
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2003087840A3 (en) Protein involved in cancer
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
WO2001064876A3 (en) Human schizophrenia gene
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
WO2002090991A3 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
NZ512332A (en) Potassium channel interactors and uses therefor
WO2004048549A3 (en) Dep-1 receptor protein tyrosine phosphatase interacting proteins and related methods
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase